venous endothelium Inhibitors
1 drugsAbout venous endothelium
The venous endothelium is the inner lining of veins, regulating vascular tone, permeability, and inflammation within the venous system. Its specialized characteristics distinguish it from other endothelia, making it relevant for targeted therapies.
The venous endothelium presents a relatively underexplored target for drug development, particularly where venous dysfunction plays a significant role. Currently, there is no genetic evidence directly linking the venous endothelium to specific diseases.
VARITHENA is the only FDA-approved drug targeting the venous endothelium, developed by PROVENSIS. It is a small molecule approved in 2013 for one indication.
Top venous endothelium Drugs
PROVENSIS is the only company with an approved drug targeting the venous endothelium.
The lack of competition suggests high barriers to entry or untapped potential.
venous endothelium Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets venous endothelium, using small molecule modality.
Exploring alternative modalities like antibodies or biologics represents a whitespace opportunity.
venous endothelium Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on venous endothelium. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 7 | 6 | 1 | 0 | 86% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 8 | 3 | 3 | 2 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
venous endothelium Drug Approval Timeline (2013 - 2013)
VARITHENA was approved in 2013 and remains the only approved drug to date.
The absence of recent approvals indicates a potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 11 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on venous endothelium. A trial counts if an approved drug acting on venous endothelium is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.